Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN).

Full DD Report for ACHN

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACHN)

Institutional Top Ideas Series: Opaleye Management
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund we´ve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds ...
Source: SeekingAlpha
Date: May, 17 2018 01:52
Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress
- Oral presentation discussing ACH-4471 and interim biomarker data from the ongoing 14-day Phase 2 study in C3G - - Poster presentation detailing in vitro data showing no significant reduction in serum bactericidal activity with factor D inhibition - NEW HAVEN, Conn., May 11, 2018 (...
Source: GlobeNewswire
Date: May, 11 2018 06:05
Wired News -Esperion Reported Positive Top-line Results from Late Stage Safety Study of its Cholestrol Drug - Bempedoic Acid
Stock Monitor: Achillion Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Esperion Therapeutics, Inc. (NASDAQ: ESPR ) all you need to do is sign up now by clicking the following link www.active-investors.com/regi...
Source: ACCESSWIRE IA
Date: May, 04 2018 07:35
Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference
NEW HAVEN, Conn., May 04, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43 rd Annual Health Care Conference on Tuesday, ...
Source: GlobeNewswire
Date: May, 04 2018 06:35
Achillion Pharmaceuticals misses by $0.01
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 EPS of -$0.15 misses by $0.01 . Cash, cash equivalents, marketable securities and interest receivable of $308.4M Shares +0.53% PM. Press Release More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare ...
Source: SeekingAlpha
Date: May, 02 2018 09:07
Achillion Reports First Quarter 2018 Financial Results and Management Transition
 - Plans for clinical data in C3 glomerulopathy (C3G) and for paroxysmal nocturnal hemoglobinuria (PNH) remain on track for 2018 -  - Joseph Truitt appointed Chief Executive Officer - NEW HAVEN, Conn., May 02, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nas...
Source: GlobeNewswire
Date: May, 02 2018 06:35
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph...
Source: SeekingAlpha
Date: April, 09 2018 13:39
Investor Expectations to Drive Momentum within Credicorp, Essent Group, Achillion Pharmaceuticals, Banco Santander, S.A, Check Point Software Technologies, and Fomento Economico Mexicano S.A.B. de C.V - Discovering Underlying Factors of Influence
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Credicorp Ltd. (NYSE:BAP), Essent Group Ltd. (NYSE:ESNT), Achillion Phar...
Source: GlobeNewswire
Date: April, 09 2018 08:30
Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 14: Market conditions continue with extreme volatility. The Market Momentum Gauge indicators are now a subscription based forecasting feature to help gauge the expected momentum conditions for the week ahead. The total return of the Breakout Stock select...
Source: SeekingAlpha
Date: March, 31 2018 09:55
Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 16 2018 15:11

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-173.563.593.623.51888,520
2017-06-204.384.514.614.34171,909,947
2017-06-194.224.374.394.22970,214
2017-06-164.114.234.234.0652,451,532
2017-06-154.214.164.274.085734,582

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-15148,473245,14260.5661Short
2018-08-1485,820184,81746.4351Short
2018-08-1343,327204,65721.1705Cover
2018-08-10295,707387,42376.3267Short
2018-08-09214,516928,35223.1072Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACHN.


About Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

Logo for Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $496,639,659 - 05/14/2018
  • Issue and Outstanding: 138,339,738 - 05/01/2018

 


Recent Filings from (NASDAQ: ACHN)

Information for Proxy Statement under Rule 14a-101
Filing Type: DEFR14AFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 02 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ACHN)

Daily Technical Chart for (NASDAQ: ACHN)


Stay tuned for daily updates and more on (NASDAQ: ACHN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACHN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACHN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ACHN and does not buy, sell, or trade any shares of ACHN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/